28/06/2025
Recent innovations in cancer treatment have spotlighted the use of microbubbles combined with focused ultrasound (FUS) to treat breast cancer non-invasively.
This technique utilizes tiny gas-filled bubbles injected into the bloodstream, which are then activated by ultrasound waves.
When the microbubbles oscillate or collapse (a process known as cavitation), they enhance the permeability of blood vessels in the tumor.
This allows for better drug or radiation delivery while minimizing damage to surrounding healthy tissue.
One of the most significant recent efforts is a Phase 1 clinical trial led by researchers at the Sunnybrook Health Sciences Centre in Canada.
The trial, titled “MRI-guided Focused Ultrasound-stimulated Microbubbles (FUS-MB) Combined with Radiation Therapy in Breast Cancer”, demonstrated complete tumor responses in treated areas. Importantly, the treatment caused only low-grade, transient toxicities, such as minor skin irritation — indicating strong potential for safe, non-surgical tumor control.
In China, an ongoing clinical study titled "Blood Perfusion Enhancement in Invasive Breast Cancer via Ultrasound-Stimulated Microbubbles" (ClinicalTrials .gov Identifier: NCT06158217) is evaluating how ultrasound-enhanced microbubbles improve tumor perfusion and therapeutic delivery.
This trial specifically targets invasive forms of breast cancer and aims to measure increased blood flow and oxygenation during therapy.
Another major breakthrough comes from a 2024 study published in Scientific Reports, titled “Ultrasound-stimulated Microbubbles Reverse Multidrug Resistance in Triple-Negative Breast Cancer”.
This research used low-intensity pulsed ultrasound (LIPUS) with microbubbles to effectively reverse chemotherapy resistance in triple-negative breast cancer (TNBC) models.
Mechanistically, it worked through the JNK/c-Jun signaling pathway, reducing levels of multidrug resistance markers (like P-glycoprotein) and improving chemotherapy response in both in vitro and in vivo systems.
On the technology development front, Arrayus Technologies, a startup from Canada, has introduced a focused ultrasound therapy platform known as Arrayus, which is being integrated into new breast cancer clinical trials.
These trials are investigating how their device can enhance radiation effects when used alongside microbubble stimulation, aiming to deliver precise, non-invasive cancer ablation.
There’s also early evidence from immunotherapy studies showing that ultrasound-microbubble therapy can "reawaken" immune cells.
A preclinical investigation showed that focused ultrasound exposure with microbubbles increased cytokine signaling in immune cells like T-cells, thereby making the tumor microenvironment more immunologically active, which may enhance future cancer immunotherapies.